UK Markets close in 5 hrs 46 mins

CVAC Jan 2023 100.000 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
0.0500+0.0500 (-44.44%)
As of 03:01PM EDT. Market open.
Full screen
Loading interactive chart…
  • EQS Group

    CureVac Announces Financial Results for the Second Quarter and First Half of 2022 and Provides Business Update

    Issuer: CureVac / Key word(s): Quarter Results18.08.2022 / 13:05 The issuer is solely responsible for the content of this announcement.CureVac Announces Financial Results for the Second Quarter and First Half of 2022 and Provides Business Update Delivering on broad 2022 second-generation vaccine development program with expansion into modified mRNA technology in collaboration with GSK; new candidates in COVID-19 and influenza enter clinical studies Phase 1 initiated for modified COVID-19 vaccine

  • EQS Group

    CureVac Starts Phase 1 Clinical Study of Modified, Omicron-Targeting COVID-19 Vaccine Candidate

    Issuer: CureVac / Key word(s): Study18.08.2022 / 13:00 The issuer is solely responsible for the content of this announcement.CureVac Starts Phase 1 Clinical Study of Modified, Omicron-Targeting COVID-19 Vaccine Candidate Phase 1 dose-escalation study to be conducted at clinical sites in the U.S., the UK, Australia, and the Philippines Milestone demonstrates CureVac’s continued execution on comprehensive clinical program of second-generation vaccine candidates for infectious diseases TÜBINGEN, Ge

  • Reuters

    BioNTech, Pfizer sue CureVac in U.S. over COVID-19 vaccine patent claims

    COVID-19 vaccine maker BioNTech said on Tuesday that it and partner Pfizer have filed a complaint with the U.S. District Court in Massachusetts, seeking a judgment that they did not infringe U.S. patents held by rival CureVac. The lawsuit, filed Monday, said CureVac is trying to profit from the success of BioNTech and Pfizer's COVID-19 vaccines after CureVac's efforts to create its own vaccine failed.